Our Services
Medical Information
Helpful Resources
Published on: 9/28/2026
Ondansetron (Zofran) is a 5-HT3 receptor blocker prescribed to prevent and treat nausea and vomiting caused by chemotherapy, radiation, surgery and anesthesia, and it is often used off-label for gastroenteritis or severe pregnancy-related sickness. It does not reliably relieve motion sickness, vertigo-related nausea, or nausea driven by inner ear problems, and it does nothing for diarrhea, stomach pain, heartburn, headache, or the underlying infection or illness causing your symptoms. Dosing, timing, and cautions such as QT prolongation, serotonin syndrome risk, and constipation matter a great deal, so see the complete answer below before assuming it is the right fit for you. Because persistent vomiting can signal anything from a simple stomach bug to a bowel obstruction, appendicitis, or a medication side effect, controlling the symptom is not the same as identifying the cause. Take a free, instant, online symptom check to see which conditions best match what you are feeling and get clear guidance on whether to self-manage, call your doctor, or seek urgent care.
Last reviewed for medical accuracy: 09/28/2026
Ondansetron is a prescription medicine in the class of 5-HT₃ (serotonin) receptor antagonists. You might know it by the brand name Zofran. It works by blocking serotonin signals in the brain and gastrointestinal tract, which helps control nausea and vomiting. Below, we’ll cover exactly what ondansetron is used for, common off-label uses, and situations where it’s unlikely to help.
FDA-approved uses of ondansetron focus on preventing nausea and vomiting in specific medical settings:
Chemotherapy-Induced Nausea and Vomiting (CINV)
• Highly and moderately emetogenic chemotherapy regimens
• Often given before chemo, sometimes with dexamethasone or other antiemetics
• Significantly lowers the risk of acute (within 24 hours) and delayed (after 24 hours) CINV
Radiation-Induced Nausea and Vomiting (RINV)
• Applied to patients receiving total body irradiation, single high-dose fractions, or daily fractions of radiotherapy to the abdomen or pelvis
• Can be used alone or with other supportive drugs
Postoperative Nausea and Vomiting (PONV)
• Given before anesthesia or during surgery to reduce PONV risk
• Especially helpful in high-risk patients (history of motion sickness, female, non-smoker, use of volatile anesthetics)
Physicians sometimes prescribe ondansetron in situations not explicitly approved by the FDA but supported by clinical experience and research:
Note: Off-label use should always be guided by a health professional.
Ondansetron blocks serotonin (5-HT₃) receptors both centrally (in the chemoreceptor trigger zone of the brain) and peripherally (in the gastrointestinal tract). When chemotherapy, radiation, or anesthesia stimulates serotonin release, ondansetron prevents these signals from reaching areas of the brain that trigger nausea and vomiting.
Ondansetron is not a universal remedy for all types of nausea. It is unlikely to be effective for:
Before you start ondansetron, here’s what you should know:
Talk with your doctor about your full medication list to reduce risks.
If you experience any of the following while on ondansetron, contact your healthcare provider immediately:
For any symptoms that feel life-threatening or severe, seek emergency care or call your local emergency number.
If you’re not sure what’s causing your nausea or how urgent your symptoms are, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Understanding what is ondansetron used for can help you and your doctor decide if it’s the right choice for preventing nausea and vomiting in specific medical scenarios. It’s a powerful tool for chemotherapy, radiation, and surgery-related nausea—but it won’t relieve all types of sick feelings. Always discuss potential benefits and risks with your healthcare provider, and for any serious or life-threatening concerns, speak to a doctor as soon as possible.
(References)
* Alfieri AB, Cubeddu LX. Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients. Br J Cancer. 1995 Oct;72(4):1013-5. doi: 10.1038/bjc.1995.452. PMID: 7547213; PMCID: PMC2034051.
* Bleiberg H, Autier P, Michaux D. Cost-effectiveness analysis of antiemetic treatment. Support Care Cancer. 1994 May;2(3):145-9. doi: 10.1007/BF00417472. PMID: 8032699.
* Tincello DG, Johnstone MJ. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Postgrad Med J. 1996 Nov;72(853):688-9. doi: 10.1136/pgmj.72.853.688. PMID: 8944215; PMCID: PMC2398636.
* Parikh PM, Shah SR, Shah SC, Sheth V, Patel RA, Shah KC, Jain PK. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis. Indian J Cancer. 1996 Mar;33(1):17-20. PMID: 9063013.
* Safonova SA, Gershanovich ML, Punanov IuA, Kolygin BA. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors]. Vopr Onkol. 1999;45(4):424-8. PMID: 10532104.
* Limebeer CL, Parker LA. The antiemetic drug ondansetron interferes with lithium-induced conditioned rejection reactions, but not lithium-induced taste avoidance in rats. J Exp Psychol Anim Behav Process. 2000 Oct;26(4):371-84. doi: 10.1037//0097-7403.26.4.371. PMID: 11056879.
* Ritter MJ, Goodman BP, Sprung J, Wijdicks EF. Ondansetron-induced multifocal encephalopathy. Mayo Clin Proc. 2003 Sep;78(9):1150-2. doi: 10.4065/78.9.1150. PMID: 12962170.
* Vadivelu S, Tomlinson K, Valles J, Hundert M, Bagdonas R, Eisenberg M. Acute anti-emetic withdrawal associated with a hemorrhagic cerebellar arteriovenous malformation. J Clin Neurosci. 2010 Aug;17(8):1061-3. doi: 10.1016/j.jocn.2009.10.038. 2010 May 21. PMID: 20488707.
* Demir HA, Batu ED, Yalçın B, Civelek E, Saçkesen C, Büyükpamukçu M. Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report. J Pediatr Hematol Oncol. 2010 Nov;32(8):e341-2. doi: 10.1097/MPH.0b013e3181ea214a. PMID: 20921907.
* Henze L, Foth S, Meller S, Twele F, Charalambous M, Kenward H, Elliott J, Pelligand L, Volk HA. Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study. J Vet Intern Med. 2022 Sep;36(5):1726-1732. doi: 10.1111/jvim.16504. 2022 Jul 29. PMID: 35906792; PMCID: PMC9511069.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.